Rilzabrutinib Shines in Phase 3 Trial of Tough-to-Treat ITP ...Middle East

Medscape - News
The oral BTK inhibitor rilzabrutinib led to rapid and durable platelet responses, reduced bleeding, and improved fatigue in patients with previously treated immune thrombocytopenia. Medscape Medical News

Read More Details
Finally We wish PressBee provided you with enough information of ( Rilzabrutinib Shines in Phase 3 Trial of Tough-to-Treat ITP )

Also on site :